

NASS 2017:

VEXIM cancels the Investor & Analyst Lunch meeting and webcast scheduled on Wednesday, October 25th

Balma, October 25th, 2017 (2 :30 PM CEST) – VEXIM, a medical device company specializing in the minimally invasive treatment of vertebral fractures listed on Euronext Growth (FR0011072602 - ALVXM), announces that following yesterday's announcement regarding the acquisition of VEXIM by Stryker Corporation, we will not hold the *Vexim Investor & Analyst Lunch Meeting & Webcast* we initially intended to have today, Wednesday, October 25th, 2017 at 12:00 PM ET (Orlando) / 6:00 PM CEST (Paris time), on the US FDA clinical trial update and go-to-market strategy.

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally invasive solutions for treating traumatic spinal pathologies. VEXIM has designed and developed the SpineJack[®], a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The company also developed the Masterflow[™], an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure. VEXIM has been listed on Euronext Growth Paris since May 3rd 2012. For further information, please visit www.vexim.com

SpineJack[®], an innovative implant for treating Vertebral Compression Fractures

The SpineJack[®] is designed to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally invasive surgery, guided by X-ray, in approximately 30 minutes, which is intended to enable the patient to be discharged shortly after surgery. The SpineJack[®] range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack[®] technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

CONTACTS

VEXIM

Vincent Gardès, CEO
José Da Gloria, Chief Financial Officer
investisseur@vexim.com
Tél. : +33 5 61 48 48 38

PRESS RELATIONS

ALIZE RP
Caroline Carmagnol / Wendy Rigal
vexim@alizerp.com
Tél. : +33 1 44 54 36 66
Tél. : +33 6 48 82 18 94



Nom : VEXIM
Code ISIN : FR0011072602
Code mnémonique : ALVXM



Deloitte | In Extenso

50 Technology Fast 50
2016 LAUREAT

